TLR9 and neoplasm: Tumor-bearing mice were treated intratumorally on days 10 and 16 post-tumor inoculation with ADU-S100, as a STING agonist, and CpG ODN1826, as a TLR9 agonist; both of these are powerful, safe, and effective immunoadjuvants with clinically translational potential.